ID

29947

Description

Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00744237

Link

https://clinicaltrials.gov/show/NCT00744237

Keywords

Versions (2)
  1. 4/29/18 4/29/18 -
  2. 4/29/18 4/29/18 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

April 29, 2018

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Hypertension NCT00744237

English

Eligibility Hypertension NCT00744237

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female, 18-85 years of age
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
blood pressure in the range of 130 to 179/80 to 109 mmhg
Description

Blood pressure determination

Data type

boolean

Alias
UMLS CUI [1]
C0005824
currently using either an ace inhibitor or an arb alone or (an ace inhibitor or an arb and up to two other drugs for treatment of high blood pressure). (patients may be on both an ace inhibitor and arb, but would need to be taken off one.)
Description

Angiotensin-Converting Enzyme Inhibitors | Angiotensin II receptor antagonist | Pharmaceutical Preparations Quantity Hypertensive disease

Data type

boolean

Alias
UMLS CUI [1]
C0003015
UMLS CUI [2]
C0521942
UMLS CUI [3,1]
C0013227
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0020538
stable medication regimen for high blood pressure for at least one month prior to screening
Description

Pharmacotherapy Stable Hypertensive disease

Data type

boolean

Alias
UMLS CUI [1,1]
C0013216
UMLS CUI [1,2]
C0205360
UMLS CUI [1,3]
C0020538
stable type 2 diabetes mellitus for at least 3 months prior to screening that is controlled by any or all of the following: diet and antidiabetic medications that may include fixed-dose insulin
Description

Non-Insulin-Dependent Diabetes Mellitus Disease length | Diet therapy | Antidiabetics | Insulin Dose Stable

Data type

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0872146
UMLS CUI [2]
C0012159
UMLS CUI [3]
C0935929
UMLS CUI [4,1]
C0021641
UMLS CUI [4,2]
C0178602
UMLS CUI [4,3]
C0205360
hgba1c 6.5 to 8.5% (this is measured at the screening visit)
Description

Hemoglobin A1c measurement

Data type

boolean

Alias
UMLS CUI [1]
C0474680
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
use of any beta blocker within one month prior to screening
Description

Adrenergic beta-Antagonists

Data type

boolean

Alias
UMLS CUI [1]
C0001645
use of clonidine within 3 months prior to screening
Description

Clonidine

Data type

boolean

Alias
UMLS CUI [1]
C0009014
diagnosis of hyperthyroidism as evidenced by abnormal lab markers
Description

Hyperthyroidism Laboratory Markers Abnormal

Data type

boolean

Alias
UMLS CUI [1,1]
C0020550
UMLS CUI [1,2]
C0162490
UMLS CUI [1,3]
C0205161
any disorder requiring the intermittent or chronic use of systemic corticosteroids
Description

Disease Requirement CORTICOSTEROIDS FOR SYSTEMIC USE Intermittent | Disease Requirement CORTICOSTEROIDS FOR SYSTEMIC USE chronic

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C3653708
UMLS CUI [1,4]
C0205267
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C1514873
UMLS CUI [2,3]
C3653708
UMLS CUI [2,4]
C0205191
diagnosis of hyperthyroidism as determined by lab markers done at screening
Description

Hyperthyroidism Determined by Laboratory Markers

Data type

boolean

Alias
UMLS CUI [1,1]
C0020550
UMLS CUI [1,2]
C0521095
UMLS CUI [1,3]
C0162490
active liver disease as determined by lab markers
Description

Liver diseases

Data type

boolean

Alias
UMLS CUI [1]
C0023895
kidney impairment; estimated gfr < 60 ml/min/1.73 m2
Description

Renal Insufficiency | Estimated Glomerular Filtration Rate

Data type

boolean

Alias
UMLS CUI [1]
C1565489
UMLS CUI [2]
C3811844
history of heart attack, clinically significant arrhythmia, unstable angina, coronary angioplasty/bypass surgery, stroke, or tia in 3 months prior to screening
Description

Myocardial Infarction | Cardiac Arrhythmia | Angina, Unstable | Coronary angioplasty | Coronary Artery Bypass Surgery | Cerebrovascular accident | Transient Ischemic Attack

Data type

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2]
C0003811
UMLS CUI [3]
C0002965
UMLS CUI [4]
C0190211
UMLS CUI [5]
C0010055
UMLS CUI [6]
C0038454
UMLS CUI [7]
C0007787
chronic heart failure
Description

Chronic heart failure

Data type

boolean

Alias
UMLS CUI [1]
C0264716
drug or alcohol abuse within 2 years prior to screening
Description

Substance Use Disorders

Data type

boolean

Alias
UMLS CUI [1]
C0038586
history of sensitivity to any beta blocker, hctz, sulfa drug, or calcium channel blocker
Description

BETA BLOCKER ALLERGY | Hydrochlorothiazide allergy | Allergy to sulfonamides | Calcium-channel blocker allergy

Data type

boolean

Alias
UMLS CUI [1]
C0741466
UMLS CUI [2]
C0571898
UMLS CUI [3]
C0038757
UMLS CUI [4]
C0570913
participation in another research study within 30 days prior to screening
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
Back to the top of the page

Similar models

Eligibility Hypertension NCT00744237

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
male or female, 18-85 years of age
boolean
C0001779 (UMLS CUI [1])
Blood pressure determination
Item
blood pressure in the range of 130 to 179/80 to 109 mmhg
boolean
C0005824 (UMLS CUI [1])
Angiotensin-Converting Enzyme Inhibitors | Angiotensin II receptor antagonist | Pharmaceutical Preparations Quantity Hypertensive disease
Item
currently using either an ace inhibitor or an arb alone or (an ace inhibitor or an arb and up to two other drugs for treatment of high blood pressure). (patients may be on both an ace inhibitor and arb, but would need to be taken off one.)
boolean
C0003015 (UMLS CUI [1])
C0521942 (UMLS CUI [2])
C0013227 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0020538 (UMLS CUI [3,3])
Pharmacotherapy Stable Hypertensive disease
Item
stable medication regimen for high blood pressure for at least one month prior to screening
boolean
C0013216 (UMLS CUI [1,1])
C0205360 (UMLS CUI [1,2])
C0020538 (UMLS CUI [1,3])
Non-Insulin-Dependent Diabetes Mellitus Disease length | Diet therapy | Antidiabetics | Insulin Dose Stable
Item
stable type 2 diabetes mellitus for at least 3 months prior to screening that is controlled by any or all of the following: diet and antidiabetic medications that may include fixed-dose insulin
boolean
C0011860 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0012159 (UMLS CUI [2])
C0935929 (UMLS CUI [3])
C0021641 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C0205360 (UMLS CUI [4,3])
Hemoglobin A1c measurement
Item
hgba1c 6.5 to 8.5% (this is measured at the screening visit)
boolean
C0474680 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Adrenergic beta-Antagonists
Item
use of any beta blocker within one month prior to screening
boolean
C0001645 (UMLS CUI [1])
Clonidine
Item
use of clonidine within 3 months prior to screening
boolean
C0009014 (UMLS CUI [1])
Hyperthyroidism Laboratory Markers Abnormal
Item
diagnosis of hyperthyroidism as evidenced by abnormal lab markers
boolean
C0020550 (UMLS CUI [1,1])
C0162490 (UMLS CUI [1,2])
C0205161 (UMLS CUI [1,3])
Disease Requirement CORTICOSTEROIDS FOR SYSTEMIC USE Intermittent | Disease Requirement CORTICOSTEROIDS FOR SYSTEMIC USE chronic
Item
any disorder requiring the intermittent or chronic use of systemic corticosteroids
boolean
C0012634 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C3653708 (UMLS CUI [1,3])
C0205267 (UMLS CUI [1,4])
C0012634 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C3653708 (UMLS CUI [2,3])
C0205191 (UMLS CUI [2,4])
Hyperthyroidism Determined by Laboratory Markers
Item
diagnosis of hyperthyroidism as determined by lab markers done at screening
boolean
C0020550 (UMLS CUI [1,1])
C0521095 (UMLS CUI [1,2])
C0162490 (UMLS CUI [1,3])
Liver diseases
Item
active liver disease as determined by lab markers
boolean
C0023895 (UMLS CUI [1])
Renal Insufficiency | Estimated Glomerular Filtration Rate
Item
kidney impairment; estimated gfr < 60 ml/min/1.73 m2
boolean
C1565489 (UMLS CUI [1])
C3811844 (UMLS CUI [2])
Myocardial Infarction | Cardiac Arrhythmia | Angina, Unstable | Coronary angioplasty | Coronary Artery Bypass Surgery | Cerebrovascular accident | Transient Ischemic Attack
Item
history of heart attack, clinically significant arrhythmia, unstable angina, coronary angioplasty/bypass surgery, stroke, or tia in 3 months prior to screening
boolean
C0027051 (UMLS CUI [1])
C0003811 (UMLS CUI [2])
C0002965 (UMLS CUI [3])
C0190211 (UMLS CUI [4])
C0010055 (UMLS CUI [5])
C0038454 (UMLS CUI [6])
C0007787 (UMLS CUI [7])
Chronic heart failure
Item
chronic heart failure
boolean
C0264716 (UMLS CUI [1])
Substance Use Disorders
Item
drug or alcohol abuse within 2 years prior to screening
boolean
C0038586 (UMLS CUI [1])
BETA BLOCKER ALLERGY | Hydrochlorothiazide allergy | Allergy to sulfonamides | Calcium-channel blocker allergy
Item
history of sensitivity to any beta blocker, hctz, sulfa drug, or calcium channel blocker
boolean
C0741466 (UMLS CUI [1])
C0571898 (UMLS CUI [2])
C0038757 (UMLS CUI [3])
C0570913 (UMLS CUI [4])
Study Subject Participation Status
Item
participation in another research study within 30 days prior to screening
boolean
C2348568 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial